Research graph
References from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Harnessing T cells to fight cancer with BiTE® antibody constructs–past developments and future directions
10.1111/imr.12393 · 2016 · External reference
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
10.1097/cco.0000000000000869 · 2022 · External reference
Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors
10.1200/po-24-00753 · 2025 · External reference
Recent development in bispecific antibody immunotherapy for hematological malignancies
10.1016/j.critrevonc.2025.104752 · 2025 · External reference
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · 2023 · External reference
Overall survival benefit with tebentafusp in metastatic uveal melanoma
10.1056/nejmoa2103485 · 2021 · External reference
Unresolved reference
2022 · External reference
GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity
10.1371/journal.pone.0031686 · 2012 · External reference
GUCY2C: at the intersection of obesity and cancer
10.1016/j.tem.2013.01.001 · 2013 · External reference
GUCY2C-targeted cancer immunotherapy: past, present and future
10.1007/s12026-011-8253-7 · 2011 · External reference
Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues
10.1073/pnas.93.25.14827 · 1996 · External reference
Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers
10.1371/journal.pone.0189953 · 2017 · External reference
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract
10.1016/j.humpath.2004.12.002 · 2005 · External reference
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies
10.2217/bmm-2020-0359 · 2021 · External reference
A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers
10.1158/1078-0432.ccr-19-3275 · 2020 · External reference
Increased tight junctional permeability is associated with the development of colon cancer
10.1093/carcin/20.8.1425 · 1999 · External reference
Increased tight junction permeability can result from protein kinase C activation/translocation and act as a tumor promotional event in epithelial cancers
10.1111/j.1749-6632.2000.tb05246.x · 2000 · External reference
Abstract 4549: evaluation of GUCY2c-CD3 bispecific targeting GI cancers in an orthotopic colorectal tumor model
10.1158/1538-7445.am2020-4549 · 2020 · External reference
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
10.1016/j.yrtph.2017.09.001 · 2017 · External reference
Summarizing historical information on controls in clinical trials
10.1177/1740774509356002 · 2010 · External reference
First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
10.2967/jnumed.119.229781 · 2020 · External reference
Preclinical evaluation of 89Zr-Df-IAB22M2C PET as an imaging biomarker for the development of the GUCY2C-CD3 bispecific PF-07062119 as a T cell engaging therapy
10.1007/s11307-021-01621-0 · 2021 · External reference
Targeting solid tumors using CD3 bispecific antibodies
10.1158/1535-7163.mct-21-0073 · 2021 · External reference
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
10.3389/fonc.2025.1548446 · 2025 · External reference
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
10.1038/s41467-024-48479-8 · 2024 · External reference
FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. Silver Spring (MD)
2024 · External reference
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
10.1136/jitc-2022-005755 · 2022 · External reference
Cell-based therapies in GI cancers: current landscape and future directions
10.1200/edbk-25-471716 · 2025 · External reference
Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer
10.1200/jco.2024.42.16_suppl.2518 · 2024 · External reference
A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
10.1007/s00280-023-04507-w · 2023 · External reference
